IgG4
Recent data from Kiszel et al (2023) provide evidence that IgG4 is a
major mediator of mRNA vaccine-induce autoimmune disease. The most
abundant antibody (also called immunoglobulin) isotype in the human
serum (blood is different from mucosa where IgA dominates) is
immunoglobulin G (IgG). The subclasses of IgG are very similar but
differ in their constant regions (the region of antibody used to destroy
antigens). Each subclass has a unique profile in terms of antigen
binding, immune complex formation, complement activation and triggering
of effector cell activation. After antigenic stimuli, IgG3 and IgG1, the
two main complement-activating subclasses are secreted first, whereas
IgG2 and IgG4, which are formed later, are thought to play a role in
attenuating inflammation due to their inability to activate complement.
Previous studies have found that antibody responses to viral protein
antigens are mainly restricted to IgG1 and IgG3. IgG2 is stimulated
primarily by carbohydrate antigens, whereas IgG4 is produced in response
to helminthic (parasitic worms) infections or to, very importantly to
mechanisms of action in mRNA vaccine injury, prolonged antigen
stimulations. mRNA vaccination yields a higher antibody titer than does
the SARS-CoV-2 infection. In other words, a huge amount of antigen
presentation elicited by the mRNA vaccination induces a huge amount of
antibody production – too much. That huge antibody production means a
high level of autoantibodies, such as IgG4.
IgG4 can mediate autoimmune diseases and create gut dysbiosis and leaky
gut (Wang et al, 2018), potentially leading to a number of maladies.
However, IgG subclasses produced against protein antigens depend on
factors other than the type of pathogens or type of vaccine, such as
T-helper cell response, and the route and the site of infections or
injections. As such, the intricacies of how an individual will respond
to a particular vaccine is largely unknown. The drug companies don’t
want to know because their business model is to give a drug to as many
people as possible, and knowing about injuries is an impediment to
making money. Leave it to academic researchers who aren’t paid-off by
pharma to figure out the safety data. Alas, there is not enough money in
academia to do this well, but Kiszel et al (2023) give us important
info.
Let’s look at what mRNA vaccines do to the different antibody levels.
Here’s Figure 5 from Kiszel et al (2023).